A detailed history of Centerpoint Advisory Group transactions in Eli Lilly & CO stock. As of the latest transaction made, Centerpoint Advisory Group holds 373 shares of LLY stock, worth $301,742. This represents 0.25% of its overall portfolio holdings.

Number of Shares
373
Previous 660 43.48%
Holding current value
$301,742
Previous $545 Million 46.66%
% of portfolio
0.25%
Previous 0.54%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 06, 2025

SELL
$713.71 - $898.95 $204,834 - $257,998
-287 Reduced 43.48%
373 $291 Million
Q1 2025

Apr 22, 2025

SELL
$725.72 - $929.72 $4,354 - $5,578
-6 Reduced 0.9%
660 $545 Million
Q4 2024

Jan 30, 2025

BUY
$727.2 - $932.06 $484,315 - $620,751
666 New
666 $514 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $769B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Centerpoint Advisory Group Portfolio

Follow Centerpoint Advisory Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Centerpoint Advisory Group, based on Form 13F filings with the SEC.

News

Stay updated on Centerpoint Advisory Group with notifications on news.